Having Trouble Quitting Smoking? Cigarettes With Low Nicotine Levels Could Be The Solution

Updated Jan 15, 2025 | 09:01 AM IST

SummaryNicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Low-nicotine level of cigarettes

Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

End of Article

Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Updated Nov 17, 2026 | 09:04 PM IST

SummaryHealth Canada issued a warning against radon exposure after identifying faulty radon detectors sold online. Long-time radon exposure may cause lung cancer.
Health Canada Warns Against Faulty Radon Detectors: How The Invisible Gas In Your Home May Cause Lung Cancer

Credit: AI-generated image

Faulty radon detectors have sparked concern after Health Canada issued a warning about how inaccurate readings on devices sold online could mislead consumers. The advisory issued recently says that faulty detectors could underestimate radon levels, giving consumers a false sense of security about their exposure to the cancer-causing gas.

It talks about electronic radon monitors and home-testing kits that have previously recalled after it was found that they gave inaccurate readings.

Among the products Health Canada has previously warned against are the InkBird WiFi Radon Detector (model RD-2), Life Basis radon detectors, Hanchen Home Radon Detector and Spolehli radon detectors. The agency has also issued warnings about other radon-monitoring devices sold online.

Inaccurate readings can be problematic in both ways. A detector may report radon levels lower than they actually are, leaving people exposed to dangerous concentrations without their knowledge. On the other hand, it may report higher levels than those present, causing unnecessary panic.

Health Canada recommends that consumers choose electronic radon monitors that have passed performance testing by the Canadian National Radon Proficiency Program (C-NRPP).

What Is Radon And How Does It Enter Your Home?

Also read: Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Radon is a naturally occurring radioactive gas released when uranium in soil and rocks breaks down. It is invisible, odourless and tasteless, making it impossible to detect without specialised equipment.

The gas can enter buildings through cracks in foundations, gaps around pipes, floor drains and other openings.

While radon disperses quickly in outdoor air, it can accumulate to high concentrations indoors, especially basements and poorly-ventilated areas.

Long-term exposure to highradon levels increases the risk of lung cancer. According to Health Canada, radon is the second-leading cause of lung cancer in Canada after smoking and the leading cause among people who have never smoked.

The risk depends on both the concentration of radon in the air and how long a person is exposed. People who smoke and are exposed to radon face an even greater risk of lung cancer.

Radon Exposure & Lung Cancer

Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer

Radon decays into radioactive particles that can be inhaled through breathing. These particles release radiation that can damage the DNA of lung cells. Long-time exposure can lead to genetic changes that contribute to cancer.

The International Agency for Research on Cancer (IARC) classifies radon as a Group 1 carcinogen, meaning there is sufficient evidence that it causes cancer in humans.

How To Check Radon Levels In Your Home?

Health Canada recommends long-term testing to determine the average radon concentration in your home. A test lasting at least three months provides a more reliable assessment than short-term measurements because radon levels can fluctuate with weather, ventilation and seasonal changes.

Consumers should:

  • Choose a long-term radon testing kit that has passed C-NRPP performance testing.
  • Place the detector on the lowest level of the home that is regularly occupied like the basement.
  • Keep the device away from windows, doors, heating sources and ventilation outlets.
  • Continue testing for at least three months before interpreting the average result.

Health Canada's guideline for indoor radon is 200 becquerels per cubic metre (Bq/m³). If the average level is above this threshold, homeowners should take action within one year and consult a certified professional.

End of Article

Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Updated Nov 17, 2026 | 06:00 PM IST

SummaryPediatric Brain Tumor Consortium (PBTC)'s shutdown has impacted multiple clinical trials and research of aggressive childhood brain cancer like diffuse intrinsic pontine glioma (DIPG) and ependymoma.
Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

Credit: AI-generated image

Clinical trials investigating experimental treatments for rare, aggressive childhood brain cancers have been disrupted after the closure of a US research consortium that was in operation for 27 years.

The shutdown of the Pediatric Brain Tumor Consortium (PBTC), after the National Cancer Institute (NCI) declined to renew its funding, has caused significant delays and rendered desperate families searching for alternative treatment options.

The consortium was composed of 16 leading children's hospitals and academic medical centres across the US, aiming to investigate new treatments for aggressive brain tumours, including diffuse intrinsic pontine glioma (DIPG) and ependymoma.

The NCI informed consortium leaders about the decision in August 2025, ending its approximately $4 million annual grant. Eight ongoing clinical trials were subsequently halted, according to The New York Times.

The consortium formally dissolved in September 2026. Researchers say the disruption has affected not only ongoing studies but also the infrastructure and resources needed to develop new treatments for childhood brain cancers.

DIPG Is One Of The Most Aggressive Childhood Brain Cancers

Also read: Losing Balance While Walking? Doctors Explain When It Could Be A Neurological Warning Sign

DIPG is a rare, aggressive brain tumour that usually affects children between four and 10 years of age. It develops in the pons, a part of the brainstem which is responsible for essential functions like breathing, heart rate, coordination and balance.

Since the tumour grows within critical brain tissue and spreads through the brainstem, it cannot be removed through surgery. Clinicians describe it “like sand in grass”.

Radiation therapy is commonly used to fight the tumour but its benefits are temporary. There is currently no established treatment. The average survival after diagnosis is approximately nine to 12 months.

With limited treatment options, clinical trials investigating experimental therapies are a need of the hour for children suffering from DIPG.

Research And Clinical Trials That Were Affected Due To Funding Closure

Also read: AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida

The closure disrupted several studies exploring experimental treatments for childhood brain tumours.

One of the affected studies, PBTC-059, was a Phase 1 trial investigating CAR-T cell therapy in children with ependymoma. CAR-T therapy entails modifying a patient's immune cells to identify and attack cancer cells.

Another study, PBTC-N14, was discontinued too. Researchers at Memorial Sloan Kettering Cancer Center were investigating whether cerebrospinal fluid samples could provide genetic information similar to that obtained through an invasive brain biopsy, reducing the need for surgery in some children.

Researchers were also exploring other experimental options for DIPG, including cancer vaccines and devices that can deliver electrical stimulation to the brain.

According to the NCI's updated information, some paused trials are expected to reopen to patient enrolment in late 2026 or early 2027. But the interruption has created a significant gap and delay for families who were previously able to access these trials.

27 Years Of Research Data At Stake

Also read: Beth Dobbin's Myalgic Encephalomyelitis Campaign Gains Support From 360 Sportspeople: Why Are They Urging UK PM To Act?

The consequences of the consortium's closure extend well beyond clinical trial enrolment and patient welfare. At St. Jude Children's Research Hospital, 27 years of research data involving more than 2,000 children with rare brain tumours had to be archived.

Hundreds of biological samples, including tumour tissue, blood and spinal fluid collected from patients, also had to be returned to hospitals or destroyed if they could not be retained.

Researchers have raised concerns that losing the consortium's dedicated infrastructure and centralised data-access system could make it harder for scientists to resume these studies and build on previous findings.

Ira Dunkel, a paediatric oncologist at Memorial Sloan Kettering Cancer Center and former chair of the consortium, described the closure as “catastrophic” and one of the worst professional moments of his career.

Why Did The US Government Shut Down PBTC?

The NCI said the decision was taken to improve efficiency by moving the consortium's data into the larger Pediatric Early Phase Clinical Trials Network. The institute also said enrolment in some consortium studies had slowed.

But researchers argued that the smaller patient populations and the highly targeted nature of experimental treatments make specialised research areas particularly important.

After the decision, NCI announced that approximately $4 million would be allocated to the larger network to strengthen paediatric brain tumour research and accelerate Phase 1 clinical trials.

The $4 million grant also seemed insufficient compared to the $732 million that the NIH spends annually on childhood cancer. But according to Dunkel, it was “hugely important”.

But researchers and patient support groups have questioned whether the larger network can immediately and effectively replace the consortium's specialised expertise, proven collaborations and research infrastructure.

A bipartisan group of lawmakers from New York called wrote to Health and Human Services Secretary Robert F. Kennedy Jr., urging to reverse the decision. “We cannot afford to take this step backward,” the group said.

Families dealing with aggressive childhood brain cancers are helpless in the light of consortium closure. With some children having less than a year after diagnosis, such setbacks mean losing access to potentially life-saving or extending experimental treatment opportunities that may not become available again in time.

End of Article

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Updated Nov 17, 2026 | 04:15 PM IST

SummaryThe National Health Accounts (NHA) Estimates for India 2023–24 revealed that government health expenditure more than tripled over the past decade, rising from ₹1,29,778 crore in 2013–14 to ₹4,14,196 crore in 2023–24.
India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Credit: AI Image

India’s social security expenditure on health nearly doubled as a share of Total Health Expenditure, rising from 6% in 2013–14 to 11% in 2023–24, according to the Union Health Ministry. The spending, estimated to have crossed Rs 1 lakh crore, aims to protect individuals and families against the financial risks associated with medical treatment.

This growth has been led by whopping contributions of the government's flagship health insurance schemes such as Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), state-specific health insurance schemes, social health insurance and medical expenditure for government employees.

Private health insurance expenditure also increased, rising from 3.4% of Total Health Expenditure in 2013-14 to 10.2% in 2023-24.

Government Health Expenditure Triples In A Decade

Also read: Ayushman Bharat Turns 8: PM Modi Highlights Record Savings On Medical Expenses

According to the National Health Accounts (NHA) Estimates for India 2023-24, released by the Ministry of Health and Family Welfare, India’s government health expenditure nearly tripled over the past decade, increasing from Rs 1,29,778 crore in 2013-14 to Rs 4,14,196 crore in 2023-24.

The government’s share of Total Health Expenditure (THE) increased by 14.9 percentage points over the decade, representing a rise of nearly 52%.

The report also highlighted an increase in per-capita government health expenditure and a decline in households’ out-of-pocket spending on healthcare.

“A healthier India. Lower financial burden. Stronger healthcare for all!” Union Health Minister JP Nadda said in a post on X while sharing the data.

"The National Health Accounts 2023–24 tell a powerful story of India’s healthcare transformation over the last decade," he added.

India Moves Into The Trajectory Of Developed World, Doubles Social Security Expenditure In A Decade

Per-Capita Government Health Spending Rises 184% In A Decade

Per-capita government health expenditure increased by 184% over the decade, nearly tripling from Rs 1,042 in 2013-14 to Rs 2,959 in 2023-24.

Spending crossed Rs 2,000 in 2019-20, reaching Rs 2,014, and rose further to Rs 2,328 in 2020-21.

The highest per-capita expenditure was recorded in 2021-22 at Rs 3,169, driven by emergency COVID-19 spending. It subsequently declined by 12.1% to Rs 2,786 in 2022-23 before increasing by 6.2% to Rs 2,959 in 2023-24.

The year-on-year growth rate peaked at 36.1% in 2021-22. Among the years that recorded an increase, the lowest growth was 6.2% in 2023-24.

“These are not just numbers. They reflect a decade of sustained efforts to make quality healthcare more affordable,” Nadda said.

He attributed the progress to initiatives such as Ayushman Bharat and Ayushman Arogya Mandirs under Prime Minister Narendra Modi. He also highlighted expanded access to free medicines and diagnostics as part of efforts to strengthen healthcare delivery.

"Our commitment is simple: No family should have to choose between its health and its financial well-being. A Swasth Bharat is the foundation of a Viksit Bharat!" Nadda said.

Public Investment In Primary Healthcare Triples

Public investment in primary healthcare also nearly tripled over the decade, rising from Rs 50,010 crore in 2013-14 to Rs 1,52,771 crore in 2023-24, according to the NHA estimates.

Out-Of-Pocket Health Expenditure Falls

Read More: India Digitalizes Health Records Of 100 Crore People Under Ayushman Bharat

The share of out-of-pocket expenditure (OOPE) in Total Health Expenditure declined from 64.2% in 2013-14 to 42.7% in 2023-24, a drop of 21.5 percentage points.

This indicates that households are paying a smaller share of overall healthcare costs directly, while other financing sources, including government spending and health insurance, account for a larger share.

Government Initiatives Expanding Access To Affordable Healthcare

The Ministry also highlighted several initiatives aimed at improving access to affordable healthcare across the country. These include:

  • Free Drugs and Diagnostics Initiatives
  • Pradhan Mantri National Dialysis Programme
  • Pradhan Mantri Bhartiya Janaushadhi Pariyojana
  • Affordable Medicines and Reliable Implants for Treatment (AMRIT) pharmacies.

End of Article